Michael Lewis MD FAAP
Hospitalist
Associate Professor Medical Director, Pediatric Critical Care and Pediatric Inpatient Units Program Director, Pediatric Cystic Fibrosis Program Associate Division Director, General Pediatrics
Join to View Full Profile
4000 Cambridge StKansas City, KS 66160
Phone+1 913-588-5000
Dr. Lewis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Kansas School of MedicineResidency, Pediatrics, 2007 - 2010- University of Kansas School of MedicineClass of 2007
Certifications & Licensure
KS State Medical License 2010 - 2025
Clinical Trials
- Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy) Start of enrollment: 2012 Jul 31
- Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients Start of enrollment: 2013 Mar 01
- A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) Start of enrollment: 2018 Jun 15
Publications & Presentations
PubMed
- The impact of highly effective modulator therapy on sinusitis and dysosmia in young children with cystic fibrosis: a prospective study protocol.Christine M Liu, Jakob L Fischer, Edith T Zemanick, Jason C Woods, Karolin K Markarian
ERJ Open Research. 2025-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
